Surgery Godfather-Chapter 1964 - 1340: The Professor’s Fury
Yang Ping was truly angry this time. Despite having invested heavily in these countries, he still decided to withdraw firmly and decisively without a moment’s hesitation.
The announcement was released simultaneously through Sanbo Research Institute’s official channels, the correspondence sections of international academic journals, and the paid announcement sections of Nature and Science. The wording of the statement was precise and calm without any emotion:
"To the global medical community and patients:
Given the unreasonable regulatory barriers, academic distortions, and commercial malicious lawsuits faced by the system regulation theory and its derivative technologies (including but not limited to K Therapy) in certain countries and areas, after prudent evaluation by the team, we have decided:
1. To immediately terminate the provision of any new technology authorization, product supply, clinical training, and data support related to the system regulation theory to sixteen countries including the United States, United Kingdom, Australia, etc. (a specific list is attached).
2. The application projects already underway in these countries (including the K Therapy clinical centers) will enter an orderly withdrawal period of ninety days. We will assist in completing the transition plans for existing patients or refer them to other regions for continued treatment.
3. This decision does not affect normal cooperation with other countries and regions. The construction of the International System Medicine Transformation Alliance (ISMTA) will continue to progress; we welcome partners with an open attitude to join.
We firmly believe that medical progress should serve all humanity. However, when the environment for scientific exploration is eroded by non-scientific factors, a temporary withdrawal is to preserve the purity of its long-term development. We sincerely regret the inconvenience caused by this decision.
——Sanbo Yang Ping Research Team"
The sixteen countries on the list are precisely the core regions where Horton’s article had the greatest influence, where pharmaceutical lobbying is most active, and where regulatory trends are most closely followed. The announcement did not mention any specific conflicts, but insiders understood that this was a direct response to the siege: no debate, no retreat, just a straightforward exit, clean and without a trace of procrastination.
On the first day the news broke, the pharmaceutical sectors of Wall Street and the European stock markets rose accordingly.
The stocks of giants such as Pfizer, Novartis, and Roche saw increases of between 3% and 5%. Analysts excitedly commented: Yang Ping’s team’s withdrawal cleared the biggest theoretical challenger and potential market substitute for traditional chemotherapy drugs, targeted drugs, and biological agents. The complexity of system medicine destined it to be difficult to standardize and scale, and proactive withdrawal is wise, demonstrating the solidity of traditional research and development paths.
During an interview with CNBC, Horton appeared reserved yet confident: "This reflects a commitment to scientific rigor and patient safety. Any responsible scientist should welcome this kind of self-restraint. Complex system interventions require longer-term verification, and hasty promotion is dangerous."
Even though Berg was deeply entangled in legal troubles, he still issued a brief statement through his lawyer: "This confirms some of my concerns that the theory itself may have fundamental flaws that cannot be overcome under strict regulation."
Internal celebratory emails among pharmaceutical giants began circulating. "We successfully defended our position." "Next quarter, concentrate resources on advancing our next-generation PD-1 inhibitors and CAR-T optimization projects." "Communication with the FDA can be more proactive, emphasizing the stability benefits of mature therapies."
What they saw was a troublesome "idealist" admitting defeat and stepping down. What they calculated was the market share freed up and the regained discourse power.
After the announcement...
Houston, United States.
The chairman of the US Senate Appropriations Committee, Old Walker, was undergoing Yang Ping’s K Therapy for brain glioblastoma.
At that moment, Griffin, an oncologist at the Anderson Cancer Center, was facing one of the most difficult conversations of his career.
Sitting across from him were Old Walker and his son.
The treatment process is complex and expensive, requiring three visits to the center each week for monitoring and fine-tuning. But the effect is remarkable. After multiple treatments, the persistent low-grade fever disappeared; imaging showed that the main lesion of the intracranial tumor had reduced by 60%; now, Old Walker’s physical sensations had almost returned to normal, and he had even resumed exercising three times a week.
But today, he received an official letter from the center.
"Mr. Walker, I’m sorry." Dr. Griffin pushed a document in front of him, "This is an official notification from headquarters, the China Sanbo Research Institute. According to their decision, in ninety days, this center will no longer be authorized to provide K Therapy or related support."
Old Walker did not look at the document; he just stared at Dr. Griffin, those usually insightful eyes now cold as icy rain. "No longer authorized? What does that mean for my treatment?"
"We have three months to complete the transition. We... will do our best to find alternative solutions for you. For example, re-evaluating previous target drug combinations, or considering joining other clinical trials..."
"Alternative solutions?" Old Walker’s voice was soft, but each word was like a blade, "Dr. Griffin, you know those alternative solutions are useless to me. You personally told me that the genetic profile of my tumor shows it is insensitive to conventional pathways, and that it’s the K Therapy, based on system regulation concepts, that bypassed the traditional therapies to be effective. You are now telling me to revert to those ineffective solutions?"
"It’s the decision of the upstream technology provider, we..."
"Upstream?" Old Walker stood up, walked to the window, and turned his back to Dr. Griffin, "I am a patient. I put in tremendous effort to receive K Therapy because it is effective. Now, because of some goddamn academic dispute or commercial brawl that I have no clue about, someone is telling me that an effective treatment is being taken away? Replaced with ineffective ones? This doesn’t conform to any market logic, nor does it comply with medical ethics."
